Population pharmacokinetics and pharmacokinetics/pharmacodynamics of bendamustine in pediatric patients with relapsed/refractory acute leukemia.

@article{Darwish2014PopulationPA,
  title={Population pharmacokinetics and pharmacokinetics/pharmacodynamics of bendamustine in pediatric patients with relapsed/refractory acute leukemia.},
  author={Mohammad Atef Darwish and Gail C Megason and Mary Bond and Edward T. Hellriegel and Philmore Robertson and Thaddeus H. Grasela and Luann Phillips},
  journal={Current medical research and opinion},
  year={2014},
  volume={30 11},
  pages={
          2305-15
        }
}
OBJECTIVE The pharmacokinetic (PK) profile of bendamustine has been characterized in adults with indolent non-Hodgkin lymphoma (NHL), but remains to be elucidated in pediatric patients with hematologic malignancies. This analysis used data from a nonrandomized pediatric study in patients with relapsed/refractory acute lymphocytic leukemia or acute myeloid leukemia. METHODS Bendamustine 90 or 120 mg/m(2) (60-minute infusion) was administered on days 1 and 2 of 21 day cycles. The population PK… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 2 times. VIEW TWEETS